Table 2. Estimated deaths averted due to vaccination, 20XX – 2030, 194 countries (in million)

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Deaths averted due to vaccination** | | |
|  | **2001-2010** | **2011-2020** | **2021-2030** |
| **Total** | 29.7 (26.6-33.1) | 39.5 (36.7-42.4) | 51 (48.5-53.7) |
| **By pathogen** |  |  |  |
| Hepatitis B virus | 9.7 (9.3-10.2) | 13 (12.5-13.4) | 14 (13.6-14.4) |
| *Haemophilus influenzae* type B | 0.4 (0.3-0.4) | 1.6 (1.4-1.9) | 2.3 (2-2.6) |
| Human papillomavirus | 0 (0-0) | 0.2 (0.2-0.2) | 4.1 (4.1-4.1) |
| Japanese encephalitis | 0 (0-0) | 0 (0-0.1) | 0.1 (0.1-0.2) |
| Measles | 12.9 (9.8-16) | 15.5 (13.1-18.4) | 18.8 (16.7-21.1) |
| *Neisseria meningitidis* serogroup A (MenA) | 0 (0-0) | 0 (0-0) | 0.1 (0-0.2) |
| *Streptococcus pneumoniae* (PCV) | 0 (0-0) | 0.9 (0.8-1) | 2 (1.8-2.2) |
| Rotavirus | 0 (0-0) | 0.2 (0.2-0.2) | 0.5 (0.5-0.6) |
| Rubella | 0.3 (0.2-0.3) | 0.6 (0.5-0.6) | 0.5 (0.4-0.6) |
| Yellow fever | 0.7 (0.6-0.7) | 1.2 (1-1.3) | 1.7 (1.2-2.1) |
| Diphtheria | 0.1 (0.1-0.1) | 0.1 (0.1-0.2) | 0.2 (0.1-0.2) |
| Pertussis | 4 (3.1-4.7) | 4.5 (3.5-5.3) | 5 (3.9-5.9) |
| Tetanus | 0.4 (0.3-0.4) | 0.4 (0.3-0.4) | 0.4 (0.4-0.5) |
| TB(BCG) | 1.1 (0.6-1.5) | 1.1 (0.6-1.5) | 1.2 (0.7-1.7) |
| **By region** |  |  |  |
| AFRO | 8.8 (6.6-10.6) | 14.4 (13.1-15.9) | 23 (21.1-25) |
| EMRO | 3.1 (2.5-3.7) | 4.5 (3.9-5) | 5.7 (4.9-6.4) |
| EURO | 1.8 (1.6-2) | 2 (1.8-2.2) | 1.9 (1.7-2.1) |
| PAHO | 3.4 (3-3.8) | 3.1 (2.7-3.5) | 3.2 (2.9-3.6) |
| SEARO | 6.4 (4.3-9) | 8.5 (6.7-10.2) | 10.5 (9.1-11.9) |
| WPRO | 6.1 (5.4-7) | 7 (6.3-7.6) | 6.7 (6.2-7.3) |
| **By income group** |  |  |  |
| High income | 1.9 (1.7-2.2) | 1.9 (1.6-2.2) | 2 (1.7-2.4) |
| Upper middle income | 10.4 (9.4-11.5) | 11.3 (10.5-12.1) | 11.2 (10.5-12) |
| Lower middle income | 12.5 (9.5-15.4) | 17.9 (15.7-20.3) | 24.8 (22.4-26.9) |
| Low income | 4.8 (4-5.7) | 8.4 (7.8-9) | 13 (12.2-13.8) |

**WHO region [ description/citation]**

**World Bank income group [description/citation]**